These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36650694)

  • 41. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New hypoglycaemic therapy in frail older people with diabetes mellitus-phenotypic status likely to be more important than functional status.
    Abdelhafiz AH; Emmerton D; Sinclair AJ
    Diabetes Res Clin Pract; 2020 Nov; 169():108438. PubMed ID: 32920102
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diabetes and frailty.
    Assar ME; Laosa O; Rodríguez Mañas L
    Curr Opin Clin Nutr Metab Care; 2019 Jan; 22(1):52-57. PubMed ID: 30394893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intensive insulin therapy combined with metformin is associated with reduction in both glucose variability and nocturnal hypoglycaemia in patients with type 2 diabetes.
    Zhang Y; Zhao Z; Wang S; Zhu W; Jiang Y; Sun S; Chen C; Wang K; Mu L; Cao J; Zhou Y; Gu W; Hong J; Wang W; Ning G
    Diabetes Metab Res Rev; 2017 Oct; 33(7):. PubMed ID: 28609547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Maruthur NM; Tseng E; Hutfless S; Wilson LM; Suarez-Cuervo C; Berger Z; Chu Y; Iyoha E; Segal JB; Bolen S
    Ann Intern Med; 2016 Jun; 164(11):740-51. PubMed ID: 27088241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A retrospective cohort analysis of hypoglycaemic and cardiovascular agent use in young adults in the Irish primary care setting.
    Grimes RT; Bennett K; Hoey H; Tilson L; Henman MC
    Ir J Med Sci; 2017 May; 186(2):461-470. PubMed ID: 27534545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    van Dijk P; Bouma A; Landman GW; Groenier KH; Bilo H; Kleefstra N; van Hateren KJ
    J Diabetes Sci Technol; 2017 Mar; 11(2):438-439. PubMed ID: 27625346
    [No Abstract]   [Full Text] [Related]  

  • 51. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
    Bolen S; Feldman L; Vassy J; Wilson L; Yeh HC; Marinopoulos S; Wiley C; Selvin E; Wilson R; Bass EB; Brancati FL
    Ann Intern Med; 2007 Sep; 147(6):386-99. PubMed ID: 17638715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Management of type 2 diabetes: new or previous agents, how to choose?].
    Halimi S
    Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ; Setter SM
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study.
    Holbrook T; Tang Y; Das R; Shankar RR; Tunceli K; Williams J; Radican L; Holden SE; Morgan CL; Piercy J; Currie CJ
    Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28544081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB; Tang X; Han M; Yang J; Simó R
    Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world patient-reported rates of non-severe hypoglycaemic events in Germany.
    Kulzer B; Seitz L; Kern W
    Exp Clin Endocrinol Diabetes; 2014 Mar; 122(3):167-72. PubMed ID: 24643694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.